High-dose esomeprazole for treatment of symptomatic refractory gastroesophageal reflux disease -A prospective pH-metry/impedance-controlled study

Digestion

Volumn 80, Issue 2, 2009, Pages 112-118

  Bajbouj, Monther ^a   Becker, Valentin ^a   Phillip, Veit ^a   Wilhelm, Dirk ^a   Schmid, Roland M ^a   Meining, Alexander ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Baclofen; Esomeprazole; Gastroesophageal reflux disease; Impedance monitoring; Proton pump inhibitors; Reflux

Indexed keywords

BACLOFEN; ESOMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; PH MEASUREMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BACLOFEN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTRIC IMPEDANCE; ESOPHAGEAL PH MONITORING; ESOPHAGEAL SPHINCTER, LOWER; FEMALE; GABA AGONISTS; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67651211334     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000221146     Document Type: Article

References (36)

1. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R: The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-1511.
2. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-1456.
3. Issing WJ, Karkos PD, Perreas K, Folwaczny C, Reichel O: Dual-probe 24-hour ambulatory pH monitoring for diagnosis of laryngopharyngeal reflux. J Laryngol Otol 2004; 118: 845-848.
4. Shim KN, Hong SJ, Sung JK, Park KS, Kim SE, Park HS, Kim YS, Lim SH, Kim CH, Park MJ, Yim JY, Cho KR, Kim D, Park SJ, Jee SR, Kim JI, Park JY, Song GA, Jung HY, Lee YC, Kim JG, Kim JJ, Kim N, Park SH, Jung HC, Chung IS; The H. pylori and GERD Study Group of Korean College of Helicobacter and Upper Gastrointestinal Research: Clinical spectrum of reflux esophagitis among 25,536 Koreans who underwent a health check-up: a nationwide multicenter prospective, endoscopy-based study. J Clin Gastroenterol 2009; Epub ahead of print.
5. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-1810.
6. Armstrong D, Veldhuyzen van Zanten SJ, Barkun AN, Chiba N, Thomson AB, Smyth S, Sinclair P, Chakraborty B, White RJ; The CADET-HR Study Group: Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care -the CADET-HR Study. Aliment Pharmacol Ther 2005; 21: 1189-1202.
7. Fass R, Shapiro M, Dekel R, Sewell J: Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease -where next? Aliment Pharmacol Ther 2005; 22: 79-94.
8. Tutuian R, Vela MF, Hill EG, Mainie I, Agrawal A, Castell DO: Characteristics of symptomatic reflux episodes on acid suppressive therapy. Am J Gastroenterol 2008; 103: 1090-1096.
9. Bajbouj M, Becker V, Neuber M, Schmid RM, Meining A: Combined pH-metry/impedance monitoring increases the diagnostic yield in patients with atypical gastroesophageal reflux symptoms. Digestion 2007; 76: 223-228.
10. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell DO: Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55: 1398-1402.
11. Zerbib F, Roman S, Ropert A, des Varannes SB, Pouderoux P, Chaput U, Mion F, Vérin E, Galmiche JP, Sifrim D: Esophageal pH-impedance monitoring and symptoms analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101: 1956-1963.
12. Sifrim D, Castell D, Dent J, Kahrilas PJ: Gastroesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53: 1024-1031.
13. Becker V, Bajbouj M, Waller K, Schmid RM, Meining A: Clinical trial: persistent gastrooesophageal gastrooesophageal reflux symptoms despite standard therapy with proton pump inhibitors -a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther 2007; 26: 1355-1360.
14. Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ: Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? Am J Gastroenterol 2008; 103: 2446-2453.
15. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J: Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-1402.
16. Savarino E, Zentilin P, Tutuian R, Pohl D, Casa DD, Frazzoni M, Cestari R, Savarino V: The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008; 103: 2685-2693.
17. El-Serag HB, Graham DY, Satia JA, Rabeneck L: Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005; 100: 2600-2601.
18. Sifrim D, Mittal R, Fass R, Smout A, Castell D, Tack J, Gregersen H: Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms. Aliment Pharmacol Ther 2007; 25: 1003-1017.
19. Jeske HC, Borovicka J, von Goedecke A, Tiefenthaler W, Hohlrieder M, Heidegger T, Benzer A: Preoperative administration of esomeprazole has no influence on frequency of refluxes. J Clin Anesth 2008; 20: 191-195.
20. Babaei A, Bhargava V, Aalam S, Scadeng M, Mittal R: Effect of proton pump inhibition on the gastric volume: assessed by magnet -ic resonance imaging. Aliment Pharmacol Ther 2009; 29: 863-870.
21. Rabasseda X, Cole P: Esomeprazole: a significant advance beyond omeprazole in the treatment of acid-related disease. Drugs Today (Barc) 2001; 37: 767-781.
22. Fass R, Sontag SJ, Traxler B, Sostek M: Treatment of patients with persistent heartburn symptoms: a double-blind randomized trial. Clin Gastroenterol Hepatol 2006; 4: 50-56.
23. Kahrilas PJ: When proton pump inhibitors fail. Clin Gastroenterol Hepatol 2008; 6: 482-483.
24. Sharma N, Agrawal A, Freeman J, Vela MF, Castell D: An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6: 521-524.
25. Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee: American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1392-1413, 1413.e1-5
26. Jaspersen D, Nocon M, Labenz J, Leodolter A, Richter K, Stolte M, Vieth M, Lind T, Willich SN, Malfertheiner P: Clinical course of laryngo-respiratory symptoms in gastrooesophageal reflux disease during routine care: a 5-year follow-up. Aliment Pharmacol Ther 2009; Epub ahead of print.
27. Robertson CS, Evans DF, Ledingham SJ, Atkinson M: Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 181-190.
28. Achem SR, Robinson M: A prokinetic approach to treatment of gastroesophageal reflux disease. Dig Dis 1998; 16: 38-46.
29. Castell DO, Sigmund C Jr, Patterson D, Lambert R, Hasner D, Clyde C, Zeldis JB: Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group. Am J Gastroenterol 1998; 93: 547-552.
30. Blackshaw LA, Staunton E, Lehmann A, Dent J: Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 1999; 277:G867-G874.
31. Lehmann A, Antonsson M, Bremner-Danielsen M, Flärdh M, Hansson-Brändén L, Kärrberg L: Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999; 117: 1147-1154.
32. Ciccaglione AF, Marzio L: Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003; 52: 464-470.
33. Vela MF, Tutuian R, Katz PO, Castell DO: Baclofen decreases acid and non-acid postprandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17: 243-251.
34. Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO: Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006; 93: 1483-1487.
35. del Genio G, Tolone S, del Genio F, Rossetti G, Brusciano L, Pizza F, Fei L, del Genio A: Total fundoplication controls acid and nonacid reflux: evaluation by pre-and postoperative 24-h pH-multichannel intraluminal impedance. Surg Endosc 2008; 22: 2518-2523.
36. Katz PO: Medical therapy for gastroesophageal reflux disease in 2007. Rev Gastroenterol Disord 2007; 7: 193-203.